drotebanol drotebanol drotebanol (oxymethebanol) is a morphinan derivative that acts as an opioid agonist. it was invented by sankyo company in japan during the 1970s. it is synthesised from thebaine. drotebanolclinical dataother namesdrotebanol, oxymethebanolahfs/drugs.cominternational drug namesatc codenonelegal statuslegal status au: s8 (controlled drug) ca: schedule i de: anlage i (authorized scientific use only) us: schedule i identifiers iupac name 3,4-dimethoxy-17-methylmorphinan-6β,14-diol cas number3176-03-2 npubchem cid5463863chemspider16736125 yunii7rs2q8mck8keggd01496 ychemblchembl2104603 nchemical and physical dataformulac19h27no4molar mass333.428 g·mol−13d model (jsmol)interactive imagemelting point165 to 167 °c (329 to 333 °f) smiles cn1cc23c(cc2(1cc4=c3c(=c(c=c4)oc)oc)o)o inchi inchi=1s/c19h27no4/c1-20-9-8-18-11-13(21)6-7-19(18,22)15(20)10-12-4-5-14(23-2)17(24-3)16(12)18/h4-5,13,15,21-22h,6-11h2,1-3h3/t13-,15-,18-,19-/m1/s1 ykey:lcahpiflpicnrw-svynmnnpsa-n y ny (what is this?) (verify) drotebanol has powerful antitussive (cough suppressant) effects, and is around 10x more potent than codeine in producing this effect. it also has analgesic effects several times stronger than codeine, but weaker than morphine. in animal studies it was found to be moderately addictive and produced limited physical dependence, but not as severe as that seen with morphine or pethidine. it was previously marketed for human use under the brand name metebanyl, although it is now no longer used in medicine. it is currently a schedule i narcotic controlled substance in the united states with a dea acscn of 9335 and an annual aggregate manufacturing quota of zero.